[1] Li SS,Mody CH.Proceedings of the American Thoracic Society[J].Cryptococcus,2010,7(3):186-196.
[2] Khawcharoenporn T,Apisarnthanarak A,Mundy LM.Non-neoformans cryptococcal infections:a systematic review[J].Infection,2007,35(2):51-58.
[3] Galanis E,Macdougall L,Kidd S,et al.Epidemiology of Cryptococcus gattii,British Columbia,Canada,1999-2007[J].Emerg Infect Dis,2010,16(2):251-257.
[4] Garcia-Hermoso D,Janbon G,Dromer F.Epidemiological evidence for dormant Cryptococcus neoformans infection[J].J Clin Microbiol,1999,37(10):3204-3209.
[5] Lortholary O,Poizat G,Zeller V,et al.Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy[J].AIDS,2006,20(17):2183-2191.
[6] Voelz K,May RC.Cryptococcal interactions with the host immune system[J].Eukaryot Cell,2010,9(6):835-846.
[7] Kozel TR,Wilson MA,Murphy JW.Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans[J].Infect Immun,1991,59(9):3101-3110.
[8] Pietrella D,Corbucci C,Perito S,et al.Mannoproteins from Cryptococcus neoformans promote dendritic cell maturation and activation[J].Infect Immun,2005,73(2):820-827.
[9] Syme RM,Spurrell JC,Amankwah EK,et al.Primary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fcgamma receptor II for presentation to T lymphocytes[J].Infect Immun,2002,70(11):5972-5981.
[10] Kelly RM,Chen J,Yauch LE,et al.Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans[J].Infect Immun,2005,73(1):592-598.
[11] Osterholzer JJ,Milam JE,Chen GH,T et al.Role of dendritic cells and alveolar macrophages in regulating early host defense against pulmonary infection with Cryptococcus neoformans[J].Infect Immun,2009,77(9):3749-3758.
[12] Shao X,Mednick A,Alvarez M,et al.An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia[J].Journal of Immunology,2005.175(5):3244-3251.
[13] Chaturvedi V,Wong B,Newman SL.Oxidative killing of Cryptococcus neoformans by human neutrophils.Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates[J].Journal of immunology,1996,156(10):3836-3840.
[14] Miller MF,Mitchell TG.Killing of Cryptococcus neoformans strains by human neutrophils and monocytes[J].Infect Immun,1991,59(1):24-28.
[15] Lehrer RI,Ganz T.Antimicrobial polypeptides of human neutrophils[J].Blood,1990,76(11):2169-2181.
[16] Mukherjee J,Nussbaum G,Scharff MD,et al.Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell[J].J Exp Med,1995,181(1):405-409.
[17] Netski D,Kozel TR.Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies:importance of epitope specificity[J].Infect Immun,2002,70(6):2812-2819.
[18] Levitz SM,Dupont MP,Smail EH.Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans[J].Infect Immun,1994,62(1):194-202.
[19] Voskoboinik I,Smyth MJ,Trapani JA.Perforin-mediated target-cell death and immune homeostasis[J].Nat Rev Immunol,2006,6(12):940-952.
[20] Kawakami K,Tohyama M,Xie Q,et al.IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans[J].Clin Exp Immunol,1996,104(2):208-214.
[21] Clemons KV,Brummer E,Stevens DA.Cytokine treatment of central nervous system infection:efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis[J].Antimicrob Agents Chemother,1994,38(3):460-464.
[22] Decken K,Kohler G,Palmer-Lehmann K,et al.Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans[J].Infect Immun,1998,66(10):4994-5000.
[23] Kawakami K,Qureshi MH,Zhang T,et al.IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production[J].Journal of immunology,1997,159(11):5528-5534.
[24] Zhang T,Kawakami K,Qureshi MH,et al.Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells[J].Infect Immun,1997,65(9):3594-3599.
[25] Joly V,Saint-Julien L,Carbon C,et al.In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis[J].J Infect Dis,1994,170(5):1331-1334.
[26] Levitz SM,Farrell TP.Growth inhibition of Cryptococcus neoformans by cultured human monocytes:role of the capsule,opsonins,the culture surface,and cytokines[J].Infect Immun,1990,58(5):1201-1209.
[27] Kawakami K,Qureshi MH,Koguchi Y,et al.Role of TNF-alpha in the induction of fungicidal activity of mouse peritoneal exudate cells against Cryptococcus neoformans by IL-12 and IL-18[J].Cell Immunol,1999,193(1):9-16.
[28] Collins HL,Bancroft GJ.Cytokine enhancement of complement-dependent phagocytosis by macrophages:synergy of tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neoformans[J].Eur J Immunol,1992,22(6):1447-1454.
[29] Zhou Q,Gault RA,Kozel TR,et al.Immunomodulation with CD40 stimulation and interleukin-2 protects mice from disseminated cryptococcosis.Infect Immun[J],2006,74(4):2161-2168.
[30] Zhou Q,Gault RA,Kozel TR,et al.Protection from direct cerebral cryptococcus infection by interferon-gamma-dependent activation of microglial cells[J].Journal of Immunology,2007,178(9):5753-5761.
[31] Rodrigues ML,Travassos LR,Miranda KR,et al.Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth[J].Infect Immun,2000,68(12):7049-7060.
[32] Rosas AL,Nosanchuk JD,Casadevall A.Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection[J].Infect Immun,2001,69(5):3410-3412.
[33] Cordero RJ,Pontes B,Frases S,et al.Antibody binding to Cryptococcus neoformans impairs budding by altering capsular mechanical properties[J].Journal of immunology,2013,190(1):317-323.
[34] Dadachova E,Nakouzi A,Bryan RA,et al.Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection[J].Proc Natl Acad Sci U S A,2003,100(19):10942-10947.
[35] Dadachova E,Bryan RA,Apostolidis C,et al.Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection[J].J Infect Dis,2006,193(10):1427-1436.
[36] Siddiqui AA,Brouwer AE,Wuthiekanun V,et al.IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis[J].Journal of immunology,2005,174(3):1746-1750.
[37] Brouwer AE,Siddiqui AA,Kester MI,et al.Immune dysfunction in HIV-seronegative,Cryptococcus gattii meningitis[J].J Infect,2007,54(3):e165-168.
[38] Pappas PG,Bustamante B,Ticona E,et al.Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis[J].J Infect Dis,2004,189(12):2185-2191.
[39] Larsen RA,Pappas PG,Perfect J,et al.Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis[J].Antimicrob Agents Chemother,2005,49(3):952-958.
[40] Perfect JR,Dismukes WE,Dromer F,et al.Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of america[J].Clin Infect Dis,2010,50(3):291-322.
[41] Pirofski LA,Casadevall A.Immunomodulators as an antimicrobial tool[J].Curr Opin Microbiol,2006,9(5):489-495.
[42] Bryan RA,Jiang Z,Howell RC,et al.Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection[J].J Infect Dis,2010,202(4):633-637. |
